Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. MorphoSys AG
  6. Summary
    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
49.94(c) 45.31(c) 45.15(c) 47.34(c) 46.97(c) Last
771 095 1 515 124 667 310 818 699 461 776 Volume
-8.67% -9.27% -0.35% +4.85% -0.78% Change
More quotes
Estimated financial data (e)
Sales 2021 171 M 203 M 203 M
Net income 2021 -170 M -202 M -202 M
Net cash position 2021 1 317 M 1 563 M 1 563 M
P/E ratio 2021 -10,1x
Yield 2021 -
Sales 2022 297 M 353 M 353 M
Net income 2022 -251 M -298 M -298 M
Net cash position 2022 459 M 545 M 545 M
P/E ratio 2022 -7,45x
Yield 2022 -
Capitalization 1 603 M 1 902 M 1 902 M
EV / Sales 2021 1,67x
EV / Sales 2022 3,85x
Nbr of Employees 607
Free-Float 95,7%
More Financials
Company
MorphoSys AG is one of the world's leading groups of biotechnology. Net sales break down by activity as follows: - development of antibody for therapeutic applications in partnership with pharmaceutical and biotechnology companies (52.2%): for treating rheumatoid arthritis, cancers and infectious diseases; - proprietary development of therapeutic antibodies and peptides (47.8%). At the end of 2019, the MorphoSys... 
More about the company
Ratings of MorphoSys AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MORPHOSYS AG
07/30MORPHOSYS AG : Notification and public disclosure of transactions by persons
EQ
07/30MORPHOSYS AG : Release according to Article 41 of the WpHG [the German Securitie..
PU
07/30MORPHOSYS AG : Release according to Article 41 of the WpHG [the German Securitie..
EQ
07/29MORPHOSYS : Reports Second Quarter and First Half 2021 Results (Form 6-K)
PU
07/29MORPHOSYS : Berenberg reaffirms its Buy rating
MD
07/29MORPHOSYS : Q2 Net Earnings Positive, Revenue Up; Raises Fiscal Full-Year Outloo..
MT
07/29MorphoSys Ag Announces Executive Changes
CI
07/29MORPHOSYS : Gets a Neutral rating from JP Morgan
MD
07/28MORPHOSYS : Reports Second Quarter and First Half 2021 Results
PU
07/28PRESS RELEASE : MorphoSys AG Reports Second -2-
DJ
07/28PRESS RELEASE : MorphoSys AG Reports Second -3-
DJ
07/28PRESS RELEASE : MorphoSys AG Reports Second Quarter and First Half 2021 Results
DJ
07/28MORPHOSYS : Reports Second Quarter and First Half 2021 Results
EQ
07/27MORPHOSYS : Commerzbank Downgrades MorphoSys to Hold Rating From Buy
MT
07/26EUROPE : European stocks ease from peaks, Prosus hits 1-year low
RE
More news
News in other languages on MORPHOSYS AG
07/30MorphoSys AG
07/30MORPHOSYS AG : Meldung und öffentliche Bekanntgabe der Geschäfte von Personen
07/30DGAP-NVR : MorphoSys AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § ..
07/29AKTIE IM FOKUS : Morphosys klettern nach Zahlen an MDax-Spitze
07/29Morphosys macht mehr Umsatz - Operativer Verlust höher
More news
Analyst Recommendations on MORPHOSYS AG
More recommendations
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 46,97 €
Average target price 103,14 €
Spread / Average Target 120%
EPS Revisions
Managers and Directors
Jean-Paul Kress CEO & Chairman-Management Board
Sung H. Lee Chief Financial Officer
Marc Cluzel Chairman-Supervisory Board
Malte Peters Chief Research & Development Officer
Roland Wandeler Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
MORPHOSYS AG-49.94%1 902
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 837